Your browser doesn't support javascript.
loading
Immunological Risk Factors in Recurrent Pregnancy Loss: Guidelines Versus Current State of the Art.
Vomstein, Kilian; Feil, Katharina; Strobel, Laura; Aulitzky, Anna; Hofer-Tollinger, Susanne; Kuon, Ruben-Jeremias; Toth, Bettina.
Afiliação
  • Vomstein K; Department of Gynecological Endocrinology and Reproductive Medicine, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
  • Feil K; Department of Gynecological Endocrinology and Reproductive Medicine, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
  • Strobel L; Department of Gynecological Endocrinology and Reproductive Medicine, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
  • Aulitzky A; Department of Gynecological Endocrinology and Reproductive Medicine, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
  • Hofer-Tollinger S; Department of Gynecological Endocrinology and Reproductive Medicine, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
  • Kuon RJ; Department of Gynecological Endocrinology and Fertility Disorders, Ruprecht-Karls University Heidelberg, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany.
  • Toth B; Department of Gynecological Endocrinology and Reproductive Medicine, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
J Clin Med ; 10(4)2021 Feb 20.
Article em En | MEDLINE | ID: mdl-33672505
ABSTRACT
Around 1-5% of all couples experience recurrent pregnancy loss (RPL). Established risk factors include anatomical, genetic, endocrine, and hemostatic alterations. With around 50% of idiopathic cases, immunological risk factors are getting into the scientific focus, however international guidelines hardly take them into account. Within this review, the current state of immunological risk factors in RPL in international guidelines of the European Society of Reproduction and Embryology (ESHRE), American Society of Reproductive Medicine (ASRM), German/Austrian/Swiss Society of Obstetrics and Gynecology (DGGG/OEGGG/SGGG) and the Royal College of Obstetricians and Gynecologists (RCOG) are evaluated. Special attention was drawn to recommendations in the guidelines regarding diagnostic factors such as autoantibodies, natural killer cells, regulatory T cells, dendritic cells, plasma cells, and human leukocyte antigen system (HLA)-sharing as well as treatment options such as corticosteroids, intralipids, intravenous immunoglobulins, aspirin and heparin in RPL. Finally, the current state of the art focusing on both diagnostic and therapeutic options was summarized.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: J Clin Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Áustria

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: J Clin Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Áustria